66 High Street
Guilford, CT 06437
Protometrix's microarray technology enables it to produce, purify, and assay thousands of proteins at once on a solid surface. With this skill set, the company believes it can become the first firm able to offer drug developers the ability to scan the entire human proteome in a high-throughput setting.
66 High Street
Guilford, CT 06437
With drug sector indexes underperforming the broad market in the first half of 2025, investors may have been anticipating tariff-related and other headwinds. But impending loss of exclusivity on key products may be provoking more anxiety at this point.
The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.
Chinese firms Junshi, Minghui and RemeGen rank among the world’s few players progressing antibody-drug conjugates combined with PD-(L)1/VEGF bispecific antibodies in Phase II trials for various cancers.